207 related articles for article (PubMed ID: 23415024)
1. The role of cytokines in the initiation and progression of myelofibrosis.
Hasselbalch HC
Cytokine Growth Factor Rev; 2013 Apr; 24(2):133-45. PubMed ID: 23415024
[TBL] [Abstract][Full Text] [Related]
2. Emerging targeted therapies in myelofibrosis.
Barosi G
Expert Rev Hematol; 2012 Jun; 5(3):313-24. PubMed ID: 22780211
[TBL] [Abstract][Full Text] [Related]
3. [Molecularly pathogenesis and molecular targeted therapy for myeloproliferative neoplasms].
Shide K
Rinsho Ketsueki; 2015 Feb; 56(2):150-8. PubMed ID: 25765794
[TBL] [Abstract][Full Text] [Related]
4. Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.
Mascarenhas J
Leuk Lymphoma; 2015; 56(9):2493-7. PubMed ID: 25586607
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapies for Myelofibrosis.
Pettit K; Odenike O
Curr Hematol Malig Rep; 2017 Dec; 12(6):611-624. PubMed ID: 29098608
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
Gregory SA; Mesa RA; Hoffman R; Shammo JM
Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
[TBL] [Abstract][Full Text] [Related]
7. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
[TBL] [Abstract][Full Text] [Related]
8. Novel therapies for myelofibrosis.
Stein BL; Cervantes F; Giles F; Harrison CN; Verstovsek S
Leuk Lymphoma; 2015; 56(10):2768-78. PubMed ID: 25860240
[TBL] [Abstract][Full Text] [Related]
9. JAK inhibitors in the treatment of myelofibrosis.
Levavi H; Hoffman R; Marcellino BK
Clin Adv Hematol Oncol; 2022 Jul; 20(7):456-467. PubMed ID: 35802878
[TBL] [Abstract][Full Text] [Related]
10. Kinase signaling and targeted therapy for primary myelofibrosis.
Yang Q; Crispino JD; Wen QJ
Exp Hematol; 2017 Apr; 48():32-38. PubMed ID: 28043820
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
Mesa RA; Tefferi A
Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
[TBL] [Abstract][Full Text] [Related]
12. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
13. Novel treatments for myelofibrosis: beyond JAK inhibitors.
Tremblay D; Mesa R
Int J Hematol; 2022 May; 115(5):645-658. PubMed ID: 35182376
[TBL] [Abstract][Full Text] [Related]
14. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
[TBL] [Abstract][Full Text] [Related]
15. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
Oh ST; Gotlib J
Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
[TBL] [Abstract][Full Text] [Related]
16. Managing patients with myelofibrosis and low platelet counts.
Al-Ali HK; Vannucchi AM
Ann Hematol; 2017 Apr; 96(4):537-548. PubMed ID: 27209535
[TBL] [Abstract][Full Text] [Related]
17. Mining for JAK-STAT mutations in cancer.
Constantinescu SN; Girardot M; Pecquet C
Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
[TBL] [Abstract][Full Text] [Related]
18. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
19. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
20. Inflammation and bone marrow fibrosis: novel immunotherapeutic targets.
Calledda FR; Malara A; Balduini A
Curr Opin Hematol; 2023 Nov; 30(6):237-244. PubMed ID: 37548363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
